Cell BioEngines

'Off-the-shelf' Curative Cell Therapies

Operating in therapeutics based in United States, Cell BioEngines was founded in 2022.

Profile

Cell BioEngines is a US-based clinical-stage biotechnology company pioneering off-the-shelf, allogeneic cell therapies. Leveraging stem cells from highly compatible super-donors and powered by its proprietary STEM-Space platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free manufacturing platform enabled by advanced biological/chemical programming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage.

Within the therapeutics space, the company focuses on its core offering rather than a broad product line.

The business is associated with United States.

Directory data places it at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Public records show total funding of about $1.3M.

Website: cellbioengines.com